piwik-script

Deutsch Intern
    Chair of orthopedic

    DFG SPP µBone

    The German Research Society (DFG) started a new Priority Program entitled "µBONE - Colonisation and Interactions of Tumor Cells within the Bone Microenvironment" (SPP 2084). Würzburg University participates in this Research Program with 2 projects of the Department of Internal Medicine II (Prof. Andreas Beilhack Research Group) and the Orthopedic Department (see project below). This project is run in close cooperation with the Department for functional materials in medicine and dentistry of Würzburg University. Within µBone several groups are dealing with breast and prostate cancer metastases to bone
    while a subgroup - including the 2 Würzburg projects - is working on the interaction of
    Multiple Myeloma with the Bone Microenvironment.


    Project Title
    Molecular and functional characterization of the normal and malignant plasma cell : bone interface
    – from single cell mutual interaction to clinical implications in angiogenesis,
    bone disease and survival

    Principal Investigators
    Franz Jakob / Regina Ebert and Dirk Hose / Anja Seckinger
    Orthopedic Department Wuerzburg University and Department of Internal Medicine V University of Heidelberg

    Background
    Myeloma cells interact with skeletal precursors and confer osteolysis and inhibition of bone regeneration. Building on previous complemen-tary and synergistic experience of our groups and network, dissecting this molecular crosstalk will reveal targets to identify, mobilize and kill niche-protected dormant myeloma cells in order to cure residual disease and reconstitute bone regeneration

    Objectives

    • Molecular and functional characterization of the bone marrow niche of normal vs. malignant plasma cells
    • Relate niche constitution and interaction factors to large cohort of patient’s malignant plasma cells and comparator populations characterized by molecular profiling and whole-body imaging
    • Functionally validate findings in vitro (CRISPR/CAS9, adherence assays) as well as in vivo (U266-myeloma mouse model)
    • Contribute to a collaborative network within and beyond µBone regarding myeloma dissemination, bone disease and angiogenesis


    Experimental Setup